A Study on the Modulation of Gut Microbiota by Oral Sialic Acid in Healthy Subjects
This is a single-center prospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The purpose of this study is to explore and clarify the effects of sialic acid intervention on gut microbiota structure, with a focus on the pr
| Condition(s) | Taking Sialic Acid to Regulate the Gut Microbiota, Healthy |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | This is a single-center prospective cohort study conducted by the Department of General Surgery at the Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). The purpose of this study is to explore and clarify the effects of sialic acid intervention on gut microbiota structure, with a focus on the proliferation of pathogens (e.g., Escherichia coli, Klebsiella pneumoniae), and to develop novel prevention and treatment strategies for improving intestinal homeostasis. |
| Who can participate | Inclusion Criteria: * Aged between 18 and 75 years * No history of major diseases, no previous surgical history, and no history of cardiometabolic diseases (such as hypertension, diabetes mellitus, obesity, etc.) * No use of drugs that may affect gut microbiota or metabolic function (e.g., antibiotics, probiotics, immunosuppressants, etc.); * Voluntarily participate in the study and sign the informed consent form. Exclusion Criteria: * Comorbidities: Complicated with other severe diseases (e.g., immunodeficiency, chronic liver disease, renal insufficiency, malignant tumors, etc.). * Recent infections: Registration records indicate a history of severe infections in the recent period (within 3 months) or currently receiving anti-infective treatment. * Special populations: Pregnant women, lac |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Xiaolong Li |
| Locations | Chongqing, Chongqing Municipality, China |
| Start date | 2025-09-10 |
| NCT ID | NCT07162662 |
| Official listing | https://clinicaltrials.gov/study/NCT07162662 |